title: SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: first therapeutic application for the treatment of osteoarthritis.
abstract: SHINBARO is a purified extract from a mixture of 6 oriental herbs (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex) that have been used as a traditional medicine for treatment of several inflammatory diseases and bone disorders. We determined antiinflammatory and antinociceptive activities of SHINBARO in adjuvant-induced (osteo)arthritis in rats. This potential anti-(osteo)arthritic property of SHINBARO can be due to the downregulation of inflammatory mediators such as iNOS, COX-2, and TNF-α, the increase of pain threshold in the peripheral system, the activation of alkaline phosphatase in osteoblasts, the suppression of proteoglycan degradation, and the inhibition of MMP-2 and MMP-9 activities as demonstrated by in vitro and in vivo experimental studies. We confirmed that SHINBARO is as effective as celecoxib, a selective COX-2 inhibitor, but it has the better safety profile in clinical trials. Finally, SHINBARO was approved as a New Herbal Medicine for treatment of osteoarthritis by Korean FDA on January 25(th), 2011.
authors.affiliation: Green Cross, 303 Bojeong-Dong, Giheung-Gu, Yongin 446-770, Korea. sylee@greencross.com
authors.forename: Sung-Yeol
authors.initials: SY
authors.lastname: Lee
authors.forename: Hyoung-Keun
authors.initials: HK
authors.lastname: Kwon
authors.forename: Sun-Mee
authors.initials: SM
authors.lastname: Lee
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D055670:Medicine, Korean Traditional; D010003:Osteoarthritis / Q000188:drug therapy*; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D056910:Republic of Korea
chemical_list: D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D061965:Matrix Metalloproteinase Inhibitors; D010936:Plant Extracts; D011480:Protease Inhibitors; C571726:shinbaro